Related Experiment Video
Updated: Jul 14, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Fast-TRKing Drug Development for Rare Molecular Targets.
Aparna R Parikh1, Ryan B Corcoran2
1Massachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Developing drugs for rare cancer targets like TRK fusions is hard. A new TRK inhibitor, LOXO-195, shows promise in overcoming resistance mutations, offering new hope for patients.
Area of Science:
- Oncology
- Drug Development
- Molecular Targets
Background:
- Drug development for rare molecular targets in oncology faces significant hurdles.
- Secondary mutations in TRK (tropomyosin receptor kinase) fusions can lead to treatment resistance.
Purpose of the Study:
- To report the accelerated development of a next-generation TRK inhibitor, LOXO-195.
- To describe an innovative initial clinical trial strategy for LOXO-195.
Main Methods:
- Development of LOXO-195, a novel TRK inhibitor.
- Design of a clinical trial strategy to evaluate LOXO-195 in patients with TRK-altered cancers.
Main Results:
- LOXO-195 is designed to overcome common secondary TRK resistance mutations.
- The study reports on the accelerated development and initial clinical trial of LOXO-195.
Conclusions:
- LOXO-195 represents a promising advancement in targeting TRK fusions.
- The development strategy addresses challenges in rare target drug discovery and resistance mechanisms.
More Related Videos
07:59Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drug Discovery: Overview
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenomics: Identification of New Drug Targets